Explore private companies with newly added funding round information.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| ClearNote Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $138.62M | Series D | 5/27/2026 | $26.73M | $275.59M | $8.10 | Prosperity Capital Management, Sandy Weill, Stephen Quake | |||||
| Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | |||||
| BigHat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $228.41M | Series C | 7/13/2026 | $80M | $452.43M | $10.01 | Undisclosed Investors | |||||
| City Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $239.04M | Series B | 6/8/2026 | $89.2M | $576.3M | $14.63 | Viking Global, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures | |||||
| Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | |||||
| Fabric | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.32M | Series B | 7/31/2026 | $230M | $959.93M | $8.22 | Undisclosed Investors | |||||
| Hazel Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.29M | Series E | 6/9/2026 | $99.03M | $396.96M | $2.40 | Undisclosed Investors | |||||
| LifeMine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $522.71M | Series E | 8/6/2026 | $150.54M | $469.78M | $0.78 | Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners | |||||
| Abcuro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $353.25M | Series D-1 | 8/18/2026 | $32.35M | $120.99M | $0.60 | New Leaf Venture Partners, Rock Springs Capital, Abrdn, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, New Enterprise Associates, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, ShangBay Capital | |||||
| Garner | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $298M | Series E | 5/28/2026 | $100M | $2.74B | $69.40 | Index Ventures, Kleiner Perkins, Redpoint Ventures, Thrive Capital, Sequoia Capital, Founders Fund, Kaiser Permanente Ventures | |||||
| Pearl Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.27M | Series C | 7/8/2026 | $50M | $284.96M | $0.67 | Andreessen Horowitz, Viking Global Investors, AlleyCorp, Ulysses Capital, Gaingels, Alumni Ventures | |||||
| CereVasc | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $198.48M | Series C-3 | 6/4/2026 | $26.43M | $275.83M | $1.04 | Piper Sandler, Johnson & Johnson, Medtronic, Bain Capital, Perceptive Advisors | |||||
| Honeycomb Insurance Services | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.54M | Series B-2 | 6/4/2026 | $35.8M | $432.12M | $6.37 | Zeev Ventures, Ibex Investors, Peakline Partners, Alpha Partners, Meitar Partners, Practical Venture Capital, Harris Barton | |||||
| Crystalys Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $102.40K | -- | 1 | -- | Not available | -- | -- | $335M | Series B | 7/22/2026 | $130M | $568.22M | $1.23 | Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology, Novo Holdings, SR One, Catalys Pacific, Perceptive Advisors, Lightstone Ventures, AN Venture Partners, Abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, Prebys Ventures | |||||
| Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | |||||
| Stepful | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $103.91M | Series C | 6/8/2026 | $52.97M | $475.35M | $26.68 | Oak HC/FT, Foresite Capital, Hearst Ventures, Citi, SemperVirens, Y Combinator, Intermountain Health, ECMC Group | |||||
| cAMPfield Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180M | Series A | 6/18/2026 | $177.98M | $297.85M | $5.22 | Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital | |||||
| Cooler Heads | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $23.97M | Series A-3 | 7/10/2026 | $3.27M | $34.04M | $1.15 | Undisclosed Investors | |||||
| GT Medical Technologies | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.98M | Series E | 6/9/2026 | $100M | $364.93M | $2.61 | Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, MedTech Venture Partners, FemHealth Ventures | |||||
| Truvian | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.15M | Series A-2 Prime | 7/14/2026 | $24.55M | $66.2M | $0.00 | Undisclosed Investors | |||||
| Barricaid | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.99M | Series V | 7/14/2026 | $25M | $115.7M | $0.66 | Undisclosed Investors | |||||
| Quanta Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series D | 6/24/2026 | $76.19M | $253.34M | $1.44 | Avidity Partners, Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, WS Investment Company | |||||
| Centivo | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $332.61M | Series C | 7/14/2026 | $107.59M | $334.91M | $1.33 | Undisclosed Investors | |||||
| NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.